2024 年第 11 期 第 19 卷

慢性乙型肝炎肝硬化的药物研究进展分析

Analysis of drug research progress in chronic hepatitis B cirrhosis

作者：钟敏王小泽杨小莉

英文作者：Zhong Min Wang Xiaoze Yang Xiaoli

单位：四川大学华西医院消化内科，成都610041

英文单位：Department of Gastroenterology West China Hospital Sichuan University Chengdu 610041 China

关键词：慢性乙型肝炎肝硬化；药物治疗；现状分析

英文关键词：ChronichepatitisBcirrhosis;Drugtreatment;Analysisofcurrentsituation

• 摘要：

• 慢性乙型肝炎为全球流行性疾病，由乙型肝炎病毒感染引发，可发展为肝硬化、肝衰竭、肝癌等不同阶段肝脏疾病。当前，慢性乙型肝炎肝硬化主要以抗病毒治疗为主，联合免疫治疗和肝脏保护治疗等方案，抗病毒药物可抑制病毒复制缓解疾病进展，肝保护治疗则主要通过抗氧化、抗炎和促进肝细胞再生来减轻肝脏损伤，新兴的治疗方法如基因编辑技术、免疫治疗药物、免疫制剂联合抗病毒以及RNA干扰疗法在预临床和临床研究中也显示出巨大的潜力。本文对现阶段慢性乙型肝炎肝硬化的药物研究进展进行了总结，并对这些治疗方法的研究进展、机制及其临床应用前景进行了详细论述。

• Chronic hepatitis B is a global epidemic disease. It is caused by hepatitis B virus infection and can develop into liver disease at different stages such as cirrhosis, liver failure, and hepatocellular carcinoma. At present, chronic hepatitis B cirrhosis is mainly treated with antiviral therapy, combined with immunotherapy and liver protective therapy. Antiviral drugs can inhibit virus replication and alleviate disease progression. Liver protective therapy mainly reduces liver injury by anti-oxidation, anti-inflammation and promoting hepatocyte regeneration. Emerging therapeutic approaches such as gene editing technology, immunotherapy drugs, immune agents combined with antiviral drugs, and RNA interference therapy have also shown great potential in pre-clinical and clinical studies. In this paper, the current research progress of drugs for chronic hepatitis B cirrhosis is summarized, and the research progress, mechanism and clinical application prospect of these treatment methods are discussed in detail.